Enzo Biochem Inc. ($0.01 Par Value)
| 3.16 | -0.0900 | -2.77% | Vol 471.11K | 1Y Perf 41.31% |
| Apr 20th, 2021 16:00 DELAYED |
| BID | 2.81 | ASK | 3.77 | ||
| Open | 3.17 | Previous Close | 3.25 | ||
| Pre-Market | - | After-Market | 3.16 | ||
| - - | - -% |
| Target Price | 12.00 | Analyst Rating | — 0.00 | |
| Potential % | 279.75 | Finscreener Ranking | ★★★★★ 59.93 | |
| Insiders Trans % 3/6/12 mo. | -/-/- | Value Ranking | ★★★+ 54.32 | |
| Insiders Value % 3/6/12 mo. | -/-/- | Growth Ranking | ★★ 47.45 | |
| Insiders Shares Cnt. % 3/6/12 mo. | -/-/- | Income Ranking | — - | |
| Market Cap | 152.40M | Earnings Rating | Buy | |
| Price Range Ratio 52W % | 44.59 | Earnings Date | 15th Mar 2021 |
Today's Price Range 3.053.23 | 52W Range 1.804.85 | 5 Year PE Ratio Range -100.90121.30 |
Summary:
Neutral
| Technical Indicators: | Neutral |
| Moving Averages: | Sell |
| Performance | |||
|---|---|---|---|
| 1 Week | -5.95% | ||
| 1 Month | -15.51% | ||
| 3 Months | 5.69% | ||
| 6 Months | 59.60% | ||
| 1 Year | 41.31% | ||
| 3 Years | -48.62% | ||
| 5 Years | -36.16% | ||
| 10 Years | -16.62% |
| Mngmt Effectiveness | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
ROE (5Y Avg) | 2.20 | |||
ROE last 12 Months | -15.20 | |||
ROA (5Y Avg) | 1.54 | |||
ROA last 12 Months | -8.83 | |||
ROC (5Y Avg) | 4.81 | |||
ROC last 12 Months | -11.07 | |||
Return on invested Capital Q | 2.51 | |||
Return on invested Capital Y | -29.51 | |||
Assets Turnover | 0.80 | |||
Receivables Turnover | 8.00 |
| Valuation | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| -15.10 | ||||
| 2.60 | ||||
| 1.62 | ||||
| 10.70 | ||||
| -11.40 | ||||
| -0.23 | ||||
| 2.98 | ||||
| 1.28 | ||||
| 147.10M | ||||
| Forward PE | -111.00 | |||
| PEG | - |
| Financial Strength | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 1.90 | ||||
| 2.30 | ||||
| 0.25 | ||||
| 0.50 | ||||
| - | ||||
| Leverage Ratio | 1.90 |
| Profitability | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 41.40 | ||||
| -6.30 | ||||
| -3.50 | ||||
| -0.50 | ||||
| -10.21 |
| Revenue | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 96.55M | ||||
| 2.00 | ||||
| -7.22 | ||||
| -4.78 |
| Dividends | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| - | ||||
| - | ||||
| - | ||||
| - | ||||
| Payout ratio | - |
| Earnings History | Estimate | Reported | Surprise % |
|---|---|---|---|
| Q01 2021 | - | 0.01 | - |
| Q04 2020 | - | -0.07 | - |
| Q03 2020 | - | -0.17 | - |
| Q02 2020 | - | -0.12 | - |
| Q01 2020 | - | -0.16 | - |
| Q04 2019 | - | -0.11 | - |
| Q03 2019 | - | -0.14 | - |
| Q02 2019 | - | -0.18 | - |
| Earnings Per End | Estimate | Revision % | Trend |
|---|---|---|---|
| 1/2018 QR | -0.01 | 0.00 | - |
| 4/2018 QR | 0.00 | - | - |
| 7/2018 FY | -0.02 | - | - |
| 7/2018 FY | -0.03 | 0.00 | - |
| Next Report Date | - |
| Estimated EPS Next Report | - |
| Estimates Count | - |
| EPS Growth Next 5 Years % | - |
| Volume Overview | |
|---|---|
| Volume | 471.11K |
| Shares Outstanding | 48.23M |
| Trades Count | 2.55K |
| Dollar Volume | 822.77K |
| Avg. Volume | 1.13M |
| Avg. Weekly Volume | 319.56K |
| Avg. Monthly Volume | 347.57K |
| Avg. Quarterly Volume | 1.27M |
Enzo Biochem Inc. ($0.01 Par Value) (NYSE: ENZ) stock closed at 3.16 per share at the end of the most recent trading day (a -2.77% change compared to the prior day closing price) with a volume of 471.11K shares and market capitalization of 152.40M. Is a component of indices and it is traded on NYSE exchange. The company belongs in the Medical Diagnostics & Research industry, Healthcare sector and employs 448 people. Enzo Biochem Inc. ($0.01 Par Value) CEO is Elazar Rabbani.
The one-year performance of Enzo Biochem Inc. ($0.01 Par Value) stock is 41.31%, while year-to-date (YTD) performance is 25.4%. ENZ stock has a five-year performance of -36.16%. Its 52-week range is between 1.8 and 4.85, which gives ENZ stock a 52-week price range ratio of 44.59%
Enzo Biochem Inc. ($0.01 Par Value) currently has a PE ratio of -15.10, a price-to-book (PB) ratio of 2.60, a price-to-sale (PS) ratio of 1.62, a price to cashflow ratio of 10.70, a PEG ratio of 2.32, a ROA of -8.83%, a ROC of -11.07% and a ROE of -15.20%. The company’s profit margin is -10.21%, its EBITDA margin is -3.50%, and its revenue ttm is $96.55 Million , which makes it $2.00 revenue per share.
Of the last four earnings reports from Enzo Biochem Inc. ($0.01 Par Value), there were 0 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $0.00 for the next earnings report. Enzo Biochem Inc. ($0.01 Par Value)’s next earnings report date is -.
The consensus rating of Wall Street analysts for Enzo Biochem Inc. ($0.01 Par Value) is — (0), with a target price of $12, which is +279.75% compared to the current price. The earnings rating for Enzo Biochem Inc. ($0.01 Par Value) stock is Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Enzo Biochem Inc. ($0.01 Par Value) has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Enzo Biochem Inc. ($0.01 Par Value) has a Neutral technical analysis rating based on Technical Indicators (ADX : 13.78, ATR14 : 0.19, CCI20 : -136.00, Chaikin Money Flow : -0.20, MACD : 0.07, Money Flow Index : 45.98, ROC : -5.52, RSI : 35.50, STOCH (14,3) : 10.42, STOCH RSI : 0.00, UO : 44.35, Williams %R : -89.58), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Enzo Biochem Inc. ($0.01 Par Value) in the last 12-months were:
Enzo Biochem Inc. ($0.01 Par Value)
Enzo Biochem Inc is a bioscience company. The firm manufactures, develops and sell their proprietary solutions and platforms to clinical laboratories, specialty clinics and researchers and physicians internationally. It focuses on delivering and applying its technology to produce products and services to allow its customers to meet their clinical needs. The company has Enzo clinical labs, Enzo life sciences, Enzo therapeutics operating segments. It derives the majority of its revenues from the Clinical lab's segment.
CEO: Elazar Rabbani
Telephone: +1 212 583-0100
Address: 527 Madison Avenue, New York 10022, NY, US
Number of employees: 448
